Resources Repository
-
ReviewWeb Portal 2015Science of Making Better Decisions About Health: CEA and BCA
This chapter reviews the main scientific methods for guiding the allocation of resources to health: cost-effectiveness …
This chapter reviews the main scientific methods for guiding the allocation of resources to health: cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA), sketches their methodological progress over the last several decades, and presents examples of how medical practice in other high-income countries, where people live longer, follows the priorities indicated by cost-effectiveness analysis.
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Policy/Regulation | Health Systems | Health/Medicine | North America -
ReviewPublication 2013Public Health Economics: Review of Guidance for Economic Evaluation
This is a systematic review of published guidance for the economic evaluation of public health …
This is a systematic review of published guidance for the economic evaluation of public health interventions. Public Health Economics is the science and art of supporting decision making as to how society can use its available resources to advance health, and minimize opportunity cost. In this review, the authors identified 5 international guidance documents, 7 UK guidance documents and 4 documents by individual commentators. The papers reviewed identify the main methodological challenges that face analysts…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Policy/Regulation | Costing Methods | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Europe -
ReviewPublication 2011Simulation Models of Obesity: A Review of the Literature
Simulation models combine information from a variety of sources to provide a useful tool for …
Simulation models combine information from a variety of sources to provide a useful tool for examining how the effects of obesity unfold over time and impact population health. They can aid in the understanding of the complex interaction of the drivers of diet and activity and their relation to health outcomes. This paper provided an overview of different types of simulation models used to evaluate the potential impact of policies to address the obesity epidemic.…
Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mathematical Models | State-Transition | Calibration/Validation | Decision Analysis | Child/Nutrition | Economics/Finance | Food/Agriculture | Health/Medicine -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Cost-Effectiveness Analysis | Policy/Regulation | Chronic Disease/Risk | Mathematical Models | Infectious Diseases | Health Systems | Health/Medicine | Global -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Priority Setting/Ethics | Technology Assessment | Policy/Regulation | Evidence Synthesis | Mathematical Models | Environmental Health | Health Systems | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | North America -
ReviewPublication 1982Decision Analysis: An Overview
This article, written for the non-decision analyst, describes what decision analysis is, what it can …
This article, written for the non-decision analyst, describes what decision analysis is, what it can and cannot do, why one should care to do this, and how one does it. Keeney describes decision analysis as "a formalization of common sense for decision problems which are too complex for informal use of common sense." He provides a more technical definition also, describing decision analysis as "a philosophy, articulated by a set of logical axioms, and a methodology…
Preferences/Values | Decision Theory | Policy/Regulation | Decision Analysis | Business/Industry | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | Military/Defense | Science/Technology -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ReviewPublication 2023Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: Methodological Review
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms …
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms in Parkinson’s disease in studies published post-2010. Methods included a systematic literature search using databases such as PubMed, EconLit, Cochrane, and several UK National Health Service databases, covering March 2010 to July 2022. The quality of the identified studies was assessed using a checklist from the German Scientific Working Group. Results showed that 20 studies were evaluated, most employing Markov…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Evidence Synthesis | Health/Medicine -
ReviewPublication 2023Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: Systematic Review
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) …
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) in at-risk adult populations. Methods included searching PubMed and Scopus for articles published between January 2016 and May 2022. The first reviewer screened all articles, while a second reviewer independently validated a random 10% sample. Discrepancies were resolved through discussion, with a third reviewer involved if necessary. Costs were standardized to 2021 euros. Reporting quality was evaluated using the CHEERS…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Evidence Synthesis | Health/Medicine